Protalix BioTherapeutics (PLX) Net Margin (2010 - 2026)

Protalix BioTherapeutics' Net Margin history runs 17 years deep, the most recent figure standing at 54.48% for Q1 2026.

• On a quarterly basis, Net Margin rose 9027.0% year-over-year to 54.48% in Q1 2026; TTM through Mar 2026 was 23.06%, a 891.0% increase from a year earlier, with the FY2025 full-year figure at 8.88%, down 2289.0% from the prior year.
• Net Margin rose to 54.48% in Q1 2026 per PLX's latest filing, from 39.29% in the prior quarter.
• Across five years, Net Margin topped out at 59.31% in Q4 2024 and bottomed at 191.91% in Q4 2023.
• The 5-year median for Net Margin is 17.9% (2023), against an average of 23.45%.
• Across the five-year window, Net Margin plunged 15466 bps in 2023 and soared 25123 bps in 2024, its largest moves.
• Year by year, Net Margin stood at 37.25% in 2022, then tumbled by 415 bps to 191.91% in 2023, then jumped by 131 bps to 59.31% in 2024, then sank by 166 bps to 39.29% in 2025, then jumped by 239 bps to 54.48% in 2026.
• Per Business Quant, the three latest PLX Net Margin figures stand at 54.48% (Q1 2026), 39.29% (Q4 2025), and 13.52% (Q3 2025).